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The programmed death (PD)-1–PD-1 ligand (PD-L) pathway, which is part of 
the B7–CD28 family, consists of the PD-1 receptor and its two ligands PD-L1 
and PD-L2. Engagement of PD-1 by its ligands inhibits immune responses, 
and recent work has shown that PD-1 is highly expressed on exhausted T cells 
during chronic lymphocytic choriomeningitis virus (LCMV) infection in mice. 
Blockade of this pathway reinvigorates the exhausted T cells, allowing them 
to expand and produce effector cytokines, raising the issue of whether this 
pathway has been exploited by a variety of viruses during chronic infection. 
New studies now extend these observations to HIV infection and 
human disease.
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PD-1 expression and signaling
PD-1 was isolated as a gene up-regu-
lated in a T cell hybridoma undergo-
ing apoptotic cell death, and was thus 
named programmed death 1 (1). PD-
1 (CD279) is inducibly expressed on 
CD4 T cells, CD8 T cells, NKT cells, 
B cells, and monocytes upon activa-
tion (for review see references 1, 2).
This broad expression of PD-1 con-
trasts with T cell–specifi  c expression of 
CD28 and CTLA-4. PD-1 transduces 
a signal when engaged in combination 
with T cell receptor (TCR) ligation, 
but does not transduce a signal when 
cross-linked alone, similar to other 
CD28 family members. The cytoplas-
mic domain of PD-1 contains two ty-
rosine signaling motifs, both of which 
may be phosphorylated upon receptor 
engagement. Phosphorylation of the 
second tyrosine, an immunoreceptor 
tyrosine–based switch motif, recruits 
the tyrosine phosphatase SHP-2 and to 
a lesser extent SHP-1 to the PD-1 cy-
toplasmic domain (3, 4). Recruitment 
of these phosphatases leads to dephos-
phorylation of TCR proximal signaling 
molecules including ZAP70, PKCθ, 
and CD3ζ, leading to attenuation of 
the TCR/CD28 signal. PD-1 signaling 
prevents CD28-mediated activation of 
phosphatidylinositol 3-kinase, resulting 
in reduced Akt phosphorylation and 
glucose metabolism.
Expression of PD-1 ligands
The PD-1 ligands have distinct patterns 
of expression. PD-L2 (B7-DC; CD273) 
is inducibly expressed only on dendritic 
cells and macrophages (for review see 
references 1, 2, 5, 6), whereas PD-L1 
(B7-H1; CD274) is broadly expressed 
on both professional and nonprofessional 
antigen-presenting cells (APCs) (1, 2, 5–7). 
PD-L1 is constitutively expressed on B 
cells, dendritic cells, macrophages, and 
T cells, and is further up-regulated upon 
activation. PD-L1 also is expressed on 
a wide variety of nonhematopoietic cell 
types, including vascular endothelial 
cells, kidney tubular epithelial cells, car-
diac myocardium, pancreatic islet cells, 
glial cells in the brain, infl  amed muscle, 
and keratinocytes. Interferons α, β, and γ 
are powerful up-regulators of PD-L1 
expression on APCs, endothelial cells, 
and epithelial cells (8, 9). During proin-
fl  ammatory immune responses, such as 
infection or transplant rejection, PD-L1 
expression is intense and extensive (10). 
For example, PD-L1 is expressed on 
liver Kupff  er cells and is up-regulated on 
hepatocytes after hepatitis B infection 
(9). PD-L1 is also expressed at sites of 
immune privilege such as the placenta 
and eye (5). PD-L1 expression is found 
on many solid tumors, and high PD-L1 
expression is associated with poor prog-
nosis (4, 5, 11, 12).
Viral exhaustion and the 
PD-1–PD-L pathway
Eff  ective antiviral CD8 T cells possess 
several functional properties including 
cytokine production (e.g., IFN-γ, 
TNF-α, IL-2), cytotoxic potential (e.g., 
perforin/granzyme granule exocytosis), 
high proliferative potential, low apop-
tosis, and, for memory T cells, the 
  ability to self-renew via homeostatic 
turnover (13). One of the key features 
of a memory CD8 T cell is the ability 
to rapidly reactivate multiple eff  ector 
functions and undergo vigorous prolif-
eration after reexposure to antigen. In 
contrast to the high functional capacity 
of eff  ector and memory CD8 T cells 
generated after acute infection or vac-
cination, CD8 T cell function is often 
impaired or exhausted during chronic 
infections. Exhaustion was originally 
described during chronic LCMV infec-
tion as the persistence of virus-specifi  c 
CD8 T cells that lacked eff  ector func-
tions (14). CD8 T cell exhaustion ap-
pears to be a prominent feature not only 
of experimental chronic infections in 
mice but also during chronic infections 
in primates and humans (for review 
see references 13, 15). For example, 
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T cells have been observed during SIV 
infection of primates and human infec-
tion with HIV, hepatitis B, hepatitis C, 
and human T lymphotropic virus-1.
Studies both in mouse models and 
human chronic infections have demon-
strated that exhaustion comprises a 
range of dysfunctions from relatively 
mild to extreme (Fig. 1) (13). Impaired 
proliferative potential is a key feature 
of exhaustion that often occurs when 
other functions, such as cytokine pro-
duction, are largely intact. Indeed, high 
proliferative potential correlates with 
nonprogression during HIV infection 
(16) and may be a critical property of 
those T cells that can respond to thera-
peutic intervention (17). There appears 
to be a distinct hierarchy of exhaustion 
with certain functional properties, such 
as IL-2 production and proliferative po-
tential, which are lost fi  rst, and other 
functions, such as IFN-γ production, 
which are more resistant to inactivation 
(Fig. 1). The duration of infection, level 
of antigen exposure, and the availability 
of CD4 T cell help are all critical factors 
that aff  ect the level of exhaustion dur-
ing any given chronic infection.
APC type and quality may also 
change dramatically during chronic in-
fections as, for example, professional 
APCs are killed and infl  ammatory sig-
nals change (18–20). It is likely that this 
altered APC repertoire and the associ-
ated changes in costimulation will in-
fl  uence T cell exhaustion during chronic 
infections. During HIV infection, sur-
face expression of PD-L1 on APCs is 
increased and that of CD86 is decreased, 
tipping the balance between inhibitory 
and stimulatory signals delivered to T 
cells toward inhibition (21). In addi-
tion, the inhibitory signals delivered by 
PD-L1 on epithelial and endothelial 
cells may take on added signifi  cance 
when professional APCs are reduced 
during chronic infection.
Recent studies have shown that 
PD-1 is highly expressed by CD8 T cells 
  during chronic LCMV infection and that 
the PD-1–PD-L pathway plays a ma-
jor role in regulating T cell exhaustion 
during this infection (22). When anti-
bodies were used to block the PD-1–
PD-L pathway in vivo during chronic 
LCMV infection, virus-specifi  c  CD8 
T cell responses were potently en-
hanced. Not only was the number of 
LCMV-specifi  c CD8 T cells increased 
dramatically, but their function was also 
improved. After in vivo PD-1–PD-L 
blockade, virus-specifi   c CD8 T cells 
produced more IFN-γ and TNF-α on 
a per cell basis. The consequence of this 
reversal of virus-specifi   c CD8 T cell 
  exhaustion was a considerable reduc-
tion in viral load. This study set the stage 
for investigations into the expres-
sion of PD-1, and the possible control 
of T cell exhaustion by the PD-1–
PD-L pathway, during human chronic 
viral infections.
The PD-1–PD-L pathway 
in HIV infection
Several new studies suggest a role for 
the PD-1–PD-L pathway in exhaustion 
of virus-specifi   c CD8 T cells during 
HIV infection. The study by Petrovas, 
et al. (on p. 2281 [23]), in this 
issue, and studies by Day et al. (24) and 
Trautmann et al. (25), published re-
cently in Nature and Nature Medicine, 
respectively, show that PD-1 expres-
sion is elevated on HIV-specifi  c CD8 T 
cells and that blocking the PD-1–PD-L 
pathway leads to increased T cell prolif-
eration and eff  ector cytokine produc-
tion (illustrated in Fig. 2). Previous work 
has shown that PD-L1 is up-regulated in 
HIV infection (21). Collectively, these 
observations suggest that the PD-1–
PD-L pathway may indeed be operating 
during chronic HIV infection.
A large percentage of HIV-specifi  c 
CD8 T cells expressed PD-1, and the 
expression of this receptor was elevated 
on a per cell basis. A large proportion of 
HIV-specifi  c CD8 T cells also expressed 
CD27 and CD45RO, indicating pre-
vious activation. These CD8 T cells 
had lost expression of the costimula-
tory   receptor CD28 and perforin and 
expressed only low levels of CCR7 and 
CD127 (IL-7 receptor α), which are im-
portant molecules for the maintenance 
of memory T cells. This phenotype 
  suggests that the T cells are poorly func-
tional, are not transiting into memory 
Figure 1.  T cell exhaustion during chronic viral infections. Virus-specifi  c CD8 T cells posses 
multiple functions including production of IFN-γ, TNF-α, IL-2, cytotoxicity, antigen-driven prolif-
eration, and resistance to apoptosis. During chronic infections, functions can be exhausted. Exhaus-
tion represents a spectrum from mild (Partial exhaustion I: little IL-2 and poor TNF-α and 
cytotoxicity) to moderate (Partial exhaustion II: modestly defective IFN-γ, cytotoxicity, and little IL-2 
or TNF-α) to severe (Full exhaustion: lack of IFN-γ, TNF-α, IL-2, and cytotoxicity). Finally, physical 
deletion (apoptosis) of T cells occurs. Proliferative potential decreases concomitantly with the loss 
of other functions while apoptosis increases. Antigen and CD4 help strongly infl  uence exhaustion; 
as antigen increases and/or CD4 help decreases, virus-specifi  c T cells become more exhausted. 
  Recent studies now identify the PD-1–PD-L pathway as a key regulator of exhaustion. Increased 
expression of PD-1 by virus-specifi  c T cells, and PD-L1 by APCs, leads to more severe exhaustion 
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cells, and are particularly receptive to 
i  nhibitory signals.
CD8 T cells in individuals infected 
with HIV have previously been shown 
to be dysfunctional with reduced pro-
liferative capacity and eff  ector function 
(13, 15, 16, 26). Day et al. show that 
disease severity, as judged by viral load 
and declining CD4 counts, correlated 
with both the level of PD-1 expres-
sion on HIV-specifi  c CD8 T cells and 
the percentage of cells expressing PD-1, 
providing a marker on CD8 T cells that 
correlates with disease severity (24). The 
level of PD-1 expression was also associ-
ated with decreased CD8 T cell prolifer-
ation in response to in vitro stimulation 
with HIV antigen. Collectively, these 
fi   ndings show that the level of PD-1 
correlates with the extent of T cell ex-
haustion. Day et al. (24) and Trautmann 
et al. (25) further demonstrated that 
PD-1 expression on HIV-specifi  c CD8 
T cells was reduced in patients undergo-
ing eff  ective highly active antiretroviral 
therapy, consistent with the notion that 
high antigen levels drive PD-1 expres-
sion and functional exhaustion. Ac-
cording to Trautmann et al., the CD8 
dysfunction did not result from changes 
in TCR expression or stimulation with 
altered peptide ligands (25).
There were striking diff  erences  in 
the levels of PD-1 expression on virus-
specifi  c T cells in chronic versus resolved 
infection. T cells specifi  c for vaccinia vi-
rus, which causes a self-limiting acute in-
fection, expressed little PD-1 compared 
with high levels of PD-1 expressed by 
HIV-specifi  c T cells. In contrast, T cells 
specifi  c for the chronic viruses, CMV and 
Epstein Barr virus, expressed moderate 
to high levels of PD-1, respectively. This 
suggests that sustained viremia and anti-
gen presentation maintain the high levels 
of PD-1 expression. It will be important 
to determine if up-regulation of PD-1 
and PD-L is a consequence of the antivi-
ral   interferon response, an indirect eff  ect 
of T cell activation and infl  ammatory cy-
tokine production, or whether HIV pro-
teins directly up-regulate their expression.
All three papers demonstrate func-
tional signifi  cance of PD-1 expression 
on HIV-specifi  c T cells. Blocking PD-
L1 with a monoclonal antibody led 
to increased T cell proliferation and 
production of TNF-α, IFN-γ, and 
granzyme B, indicating an overall in-
crease in eff  ector function. Although 
short-term blockade of the PD-1–PD-
L pathway in a 6-h cytokine assay had 
little eff  ect on HIV-specifi  c CD8 T cell 
function, blockade of this pathway dur-
ing a 6 d proliferation assay enhanced 
the proliferation of both HIV-specifi  c 
CD8 and CD4 T cells and resulted in 
more functional T cells at the end of 
the culture. Whether proliferation is 
a prerequisite for the recovery of other 
T cell functions remains to be deter-
mined. Cytolytic activity, for example, 
Figure 2.  Reinvigorating exhausted T cells. (A) Microbial products and cytokines produced in response to microbes activate APCs and stimulate 
  expression of CD80 and CD86. Engagement of CD28 by CD80/CD86 stimulates the expansion and differentiation of naive T cells into effector T cells. 
(B) Effector T cells eliminate the invading pathogens by secreting cytokines and killing infected cells. (C) Upon resolution of infection, effector T cells give 
rise to long-lived protective memory T cells. (D) However, during chronic infection, T cells lose function and the ability to proliferate and become functionally 
exhausted. Exhausted T cells express high levels of PD-1. (E) Blockade of interactions between PD-1 and its ligands can reinvigorate T cells to expand and 
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was not examined and will be of great 
interest. It is also unclear whether the 
recovery of proliferative potential ob-
served in the LCMV and HIV systems 
refl  ects greater cell division, less death, 
or both.
Petrovas et al. used a plate-bound, 
PD-1-specifi   c polyclonal antibody to 
show that engagement of PD-1 reduces 
HIV-antigen specifi  c T cell prolifera-
tion (23). They examined apoptosis in 
the PD-1+ HIV-specifi  c CD8 T cells 
and found increases in both spontaneous 
and Fas-mediated apoptosis, suggesting 
that cross-talk may occur between PD-
1 and Fas receptors. The interpretation 
of these fi  ndings, however, is compli-
cated by the fi  nding that PD-1− HIV-
specifi  c CD8 T cells also have increased 
susceptibility to apoptosis. It is possible 
that other factors such as the level of 
T cell activation are involved. Cells ex-
pressing very high levels of PD-1 were 
much more susceptible to death signals, 
suggesting that PD-1 expression leads 
to a survival defect in vivo.
Because of the link between CD4 
help and CD8 function, Day et al. also 
examined the eff  ects of PD-1 ligand 
blockade on CD4 T cell expansion 
(24). Remarkably, in fi  ve of six patients 
with undetectable CD4 proliferative 
responses to HIV p24 antigen, block-
ing PD-L1 restored vigorous CD4 
T cell expansion, suggesting that HIV-
specifi  c CD4 T cells may be present 
but so functionally impaired that they 
are undetectable in standard assays.
Infections that exploit the 
PD-1–PD-L pathway
In addition to HIV and LCMV, a variety 
of microbial pathogens appear to have 
usurped the PD-1–PD-L pathway to 
inhibit antimicrobial immunity and im-
mune-mediated host tissue damage. Dur-
ing chronic viral and parasite infections, 
up-regulation of PD-1 and its ligands 
may attenuate immune responses and 
facilitate persistence of the pathogens. 
For example, the expression of PD-1 
ligands is required for the   suppressive 
function of macrophages and the induc-
tion of T cell anergy during infections 
with the helminths Schistomosa mansoni 
and Taenia crassiceps (27). Up-regulation 
of PD-1 and its ligands might also be 
used to limit potentially detrimental 
infl  ammatory consequences of antimi-
crobial eff  ector responses. Such a pro-
tective role for PD-1 is suggested by 
studies of adenovirus-infected PD-1−/− 
mice, which more rapidly clear the virus 
but develop more severe hepatocellular 
injury than wild-type mice (1).
Concerns and unresolved issues
The PD-1–PD-L pathway has a criti-
cal role in regulating the balance be-
tween T cell activation and tolerance 
(1, 28). Blocking or eliminating PD-1 
or its ligands can accelerate and exac-
erbate autoimmune disease. Single nu-
cleotide polymorphisms in PD-1 have 
been linked with several autoimmune 
diseases, although how PD-1 aff  ects 
susceptibility to human autoimmune 
diseases is not yet clear. It will be im-
portant to learn how to modulate this 
pathway to reactivate antiviral T cells 
while minimizing the risk of autoim-
munity and immunopathology.
How does PD-1 exert its inhibitory 
eff  ects? Many reports have shown that 
PD-1 signaling inhibits T cell activation. 
Early reports found an eff   ect on cell 
cycle arrest rather than cell death (4), 
but recent studies, including the study 
by Petrovas et al., emphasize the role 
of PD-1 in promoting T cell death (9, 
12, 23). PD-1 might directly engage a 
death pathway or more likely indirectly 
infl  uence cell death by down-regulat-
ing survival signals and growth factors 
or synergizing with death pathways. 
For example, PD-1 ligation inhibits ex-
pression of the cell survival gene bcl-xl 
and several growth factors (2–5). The ef-
fects of PD-1 ligation on expression of 
death receptors and death pathways need 
further study.
The outcome of PD-1–PD-L inter-
actions on T cell expansion and survival 
might also depend on the microen-
vironment and the type of APC that 
interacts with the T cell. When mac-
rophages are used as APCs, anti–PD-
L1 or anti–PD-1 monoclonal antibody 
increases IFN-γ and IL-2 production 
by T cells but, paradoxically, inhibits 
their proliferation. This inhibition was 
caused by the IFN-γ–dependent in-
duction of nitric oxide production 
by macrophages, which inhibits T cell 
proliferation (29). Increased IFN-γ pro-
duction after PD-L1 blockade is seen in 
HIV-specifi  c T cells and is a common 
result reported in many experimental 
systems. Thus, combining inducible 
nitric oxide synthase blockade with 
PD-1–PD-L blockade may have thera-
peutic potential as a means to augment 
immune responses and protect against 
the potential proinfl  ammatory eff  ects 
of nitric oxide.
To optimally manipulate this path-
way during chronic viral infection, fur-
ther work is needed to understand the 
functions of PD-L1 versus PD-L2, and 
the role of PD-1 on B cells and mac-
rophages and on T cells. Since PD-1 is 
expressed on B cells and macrophages 
and PD-L1 is expressed on T cells, there 
might also be bidirectional signaling. 
Some reports describe reverse signaling 
of PD-L1 and PD-L2 into cells that ex-
press them (6). There are also data that 
support stimulatory functions of PD-L1 
or PD-L2, perhaps mediated by an as yet 
unidentifi  ed second receptor. The con-
tributions of each of these interactions 
to the therapeutic effi   cacy of pathway 
manipulations need to be evaluated.
Concluding remarks
The reports by Petrovas et al. (23), 
Day et al. (24), and Trautmann et al. 
(25) suggest that blocking PD-1–PD-L 
interactions may be a therapeutic strat-
egy for HIV infection that could allow 
the reactivation of anti-HIV T cell re-
sponses. Because this pathway has an 
important role in regulating the balance 
between T cell activation and tolerance, 
it will be important to identify the op-
timal timing and frequency of therapy 
to minimize the risk of immunopathol-
ogy or autoimmunity. The eff  ects  of 
blocking only PD-1, PD-L1, or PD-
L2 or a combination thereof will need 
to be evaluated for effi   cacy and safety. 
It might also be benefi  cial to combine 
PD-1 blockade with antiviral therapy 
or therapeutic vaccination. In particu-
lar, since the therapeutic eff  ects of inter-
ferons may be limited by the induction 
of PD-1 ligands, there may be syn-
ergistic benefi  ts of PD-1 blockade in COMMENTARY
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conjunction with interferon therapy. 
Further studies are needed to investigate 
to what extent, and for how long, PD-
1–PD-L blockade can restore diff  erent 
eff  ector functions, particularly cytolysis.
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